ClinicalTrials.gg
Not yet recruitingNCT06543966Updated Aug 9, 2024

Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

A Phase 3 interventional study of Aprepitant Injection and Aprepitant Injection Placebo in Post-operative Nausea and Vomiting (PONV), sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-09.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
486
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing aprepitant in Vomiting — 3 open to participants now, 3 under way, 1 of them phase 3. Aprepitant · Vomiting.

Planned enrollment
5th of 61
486 · median 92
Started
2024
with 1 other
Phase 3
15 of 61
1 open now
Registered
60th of 61
by date

Among the 61 studies testing aprepitant in Vomiting, this one is the 5th largest by planned enrollment, is one of 2 that started in 2024, is one of 15 in phase 3, and was the 60th registered.

Vomiting

794 studies on the registry are indexed under Vomiting; 99 are open to participants now.

Browse Vomiting studies →

Open to participants now

3 of the 61 studies testing aprepitant in Vomiting are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About aprepitant

Aprepitant: first FDA approval 2003 (EMEND), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Vomiting studies recruiting now, 26 (46%) set no upper age limit and 24 (43%) stop at 75 or younger; 10 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing aprepitant in Vomiting, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,

Read the detailed description

In this study, a randomized, double-blind, placebo-controlled multicenter study will be conducted to evaluate the efficacy and safety of aprepitant injection in the prevention of post-operative nausea and vomiting (PONV).

03

Conditions studied

  • Post-operative Nausea and Vomiting (PONV)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Age ≥18 and ≤75 years old; 18 \< ≤30kg/m\^2, body weight ≥45kg; laparoscopic gynecologic or abdominal surgery under general anesthesia that was expected to last at least 1 hour.

expected or agreed to stay in the hospital for 24 hours or more after surgery;

Exclusion criteria

Exclusion Criteria:

diagnostic surgery; scheduled for postoperative transfer to an intensive care unit; requiring placement of a nasogastric or orogastric tube after surgery; Post-operative vomiting may pose significant risk;

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
486 participants (estimated)

Study arms

  • Experimental
    Aprepitant Injection

    Before anesthesia induction, 4.4ml(32mg) was given by a single intravenous injection, which was completed within 30 seconds

    Drug: Aprepitant Injection

  • Placebo comparator
    Placebo

    Before anesthesia induction, 4.4ml(0mg)was given by a single intravenous injection, which was completed within 30 seconds

    Drug: Aprepitant Injection Placebo

Interventions

  • Before anesthesia induction, 4.4ml(32mg) was given by a single intravenous injection, which was completed within 30 seconds

  • DrugAprepitant Injection Placebo

    Before anesthesia induction, 4.4ml(0mg) was given by a single intravenous injection, which was completed within 30 seconds

06

What researchers measure

Primary outcomes

  1. Complete response (CR) rates over 24 hours after the end of surgery

    Complete response (defined as no emetic episodes and no use of rescue therapy)

    Time frame: 0-24 hours after the end of surgery

Secondary outcomes

  1. Proportion of participants who have no nausea in the 0 to 24 hours following the end of surgery

    No nausea(defined as a visual analogue scale (VAS) nausea score \< 1.)

    Time frame: 0-24 hours after the end of surgery

  2. Proportion of participants who have significant nausea in the 0 to 24 hours following the end of surgery

    Significant nausea(defined as a visual analogue scale (VAS) nausea score≥4)

    Time frame: 0-24 hours after the end of surgery

  3. Proportion of participants who have no vomiting or retching in the 0 to 24 hours following the end of surgery

    No vomiting or retching(Defined as whether or not use remedy treatment had no vomiting)

    Time frame: 0-24 hours after the end of surgery

  4. Proportion of participants who use the remedial treatment in the 0 to 24 hours following the end of surgery

    Time frame: 0-24 hours after the end of surgery

  5. Time to treatment failure in the 0 to 24 hours following the end of surgery

    defined as the time to the first episode of vomiting (vomiting or retching) or the time to rescue therapy, whichever occurred first.

    Time frame: 0-24 hours after the end of surgery

  6. Proportion of participants who have no vomiting or retching in the 0 to 48 hours following the end of surgery

    No vomiting or retching(Defined as whether or not use remedy treatment had no vomiting)

    Time frame: 0-48 hours after the end of surgery

  7. The time to the first episode of vomiting (vomiting or retching) in the 0 to 48 hours following the end of surgery

    Time frame: 0-48 hours after the end of surgery

Other outcomes

  1. Number of participants with treatment-related adverse events as assessed by NIH

    Safety was assessed by Adverse events (AEs) were recorded after administration.

    Time frame: Day 0 to Day14

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2024; primary completion for Mar 2026, 17 months later.

Of 56 phase 3 interventional studies under Vomiting, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Aug 9, 2024
StartEst.
Oct 28, 2024
Primary completionEst.
Mar 28, 2026
CompletionEst.
Mar 28, 2026
Last update
Aug 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06543966
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Oct 28, 2024 (estimated)
Primary completion
Mar 28, 2026 (estimated)
Completion
Mar 28, 2026 (estimated)
Last update
Aug 9, 2024

Study contacts

xiangdong chen, Doctor of Medicine(M.D.)
Contact
xiangdongchen2013@163.com
+86-027-85726300
Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
86-0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aprepitant

Start the discussion